S. Mercanti

MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

M. Sormani, D. Landi, R. Capra, 2021, Journal of the Neurological Sciences.

Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months

F. Novelli, M. Clerico, D. Horáková, 2016 .

The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View

S. Cutrupi, M. Clerico, S. Rolla, 2019, Cells.

FMR1 Premutation and Demyelinating Syndromes: Case or Causality? A Case Report

M. Clerico, M. Iudicello, Jhon Alejandro Rico Gallego, 2019, Biomedical Journal of Scientific & Technical Research.

Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses

L. Durelli, F. Novelli, M. Clerico, 2017, Journal of Neuroimmunology.

Natalizumab Discontinuation after the 24th Course: Which Is Way? The TY-STOP Study (P01.197)

M. Trojano, A. Ghezzi, S. Realmuto, 2013 .

Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia

A. Chiò, A. Calvo, L. Durelli, 2015, Journal of Neurology.

Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b

L. Durelli, E. Versino, M. Clerico, 2009 .

effect suppressor function increases up to 24 months

L. Durelli, F. Novelli, M. Clerico, 2016 .

Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey

G. Tedeschi, V. Morra, S. Bonavita, 2019, Journal of Neurology.